Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Sanofi Pharma Bristol-Myers Squibb SNC
174 Avenue de France, F-75013 Paris, France,
Telephone: +44 (0)1483 505 515 Sanofi
Telephone: +44 (0)1895 52 3000 - BMS
Fax: +44 (0)1483 535 432 or +44 (0)1895 52 3010
Medical Information Direct Line: +44 (0)800 731 1736 BMS - Aprovel and CoAprovel
Medical Information e-mail: medical.information@bms.com
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com
Medical Information Fax: +44 (0)1895 52 3677 BMS

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 11/05/2012
PIL CoAprovel 150/12.5 mg, 300/12.5 mg and 300/25 mg Film-Coated Tablet (sanofi-aventis Bristol-Myers Squibb SNC)

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 11/05/2012 and displayed until Current
Reasons for adding or updating:
  • Change to MA holder contact details
Updated on 29/02/2012 and displayed until 11/05/2012
Reasons for adding or updating:
  • Change to information about pregnancy or lactation
Updated on 15/09/2011 and displayed until 29/02/2012
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 10/06/2011 and displayed until 15/09/2011
Reasons for adding or updating:
  • Change to side-effects
Updated on 03/07/2008 and displayed until 10/06/2011
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 23/02/2007 and displayed until 03/07/2008
Reasons for adding or updating:
  • Addition of Marketing Authorisation Holder
  • Change to date of revision
Updated on 20/11/2006 and displayed until 23/02/2007
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Change of active ingredient
  • Change to appearance of the medicine
  • Change to, or new, use for medicine
  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to date of revision
  • Addition of joint PIL covering all presentations
  • Introduction of new strength
Updated on 13/09/2006 and displayed until 20/11/2006
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Active Ingredients/Generics

 
  hydrochlorothiazide
  irbesartan